DCTH vs MDT
DCTH: Interventional oncology company bringing a catheter-based chemotherapy delivery system to market for treating liver cancers, anchored by the newly FDA-approved HEPZATO kit for uveal melanoma metastases. MDT: Global medical device leader deploying pacemakers, defibrillators, spinal implants, surgical robotics, and diabetes management systems to alleviate pain, restore health, and extend life across 150+ countries.
Side-by-side fundamentals
| Metric | DCTH | MDT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $12.53 | $81.89 | |
| Market cap as of 2026-07-23 | $433M | $105.1B | |
| P/E as of 2026-07-23 | 771.04 | 21.88 | MDT lower |
| PEG as of 2026-07-23 | n/a | 2.90 | |
| Net margin as of 2026-07-23 | +0.6% | +13.2% | MDT higher |
| Gross margin as of 2026-07-23 | +86.0% | +65.3% | DCTH higher |
| Operating margin as of 2026-07-23 | -1.8% | +17.8% | MDT higher |
| ROE as of 2026-07-23 | +0.5% | +9.8% | MDT higher |
| ROA as of 2026-07-23 | +0.5% | +5.2% | MDT higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.57 | DCTH lower |
| Revenue growth (YoY) as of 2026-07-23 | +68.0% | +8.4% | DCTH higher |
| Revenue CAGR (3y) SEC XBRL | +215.3% | +5.2% | DCTH higher |
| Dividend yield as of 2026-07-23 | n/a | +3.5% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 0.53 | 0.57 | |
| 1-year return as of 2026-07-22 close | +13.2% | -10.6% | DCTH higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.